MyBlog

this is the breaking news of one scientific news channel 

  i have read this information from one of the patent

Chrono Therapeutics has unveiled a wristwatch-like device for the non-invasive automatic administration of drugs based on the amount and time instructed, thus improvingpatience compliance.

Chrono Dose is programmed like an alarm clock and worn like a watch to accurately deliver predefined-sized doses to coincide with peak disease symptoms.

I read this article from one of the pharmacy news letter.

There is concern about fractures in women using AVANDIA (rosiglitazone) and ACTOS (pioglitazone).  Health Canada is warning about use of these medications.  Women, whoever is using these drugs, seem to get more fractures of the arm, hand, ankle, and foot...but not hip or spine so far.  Similar risk is not found in men it seems. Health Canada is recommending to tell women that this doesn't prove that glitazones cause fractures, but suggest monitoring bone density in women who are at risk for fractures or falls.

1. Novartis claims that huge efforts in terms of R&D work are involved in the "invention" of imatinib mesylate (a derivative) from imatinib (a base) and hence it deserves to be given a patent on imatinib mesylate for 20 years. Since Section3(d) precludes the granting of a patent on a derivative, which comes under "mere discovery of a new from of a known substance", it should be struck down, as per the contention of Novartis. But this argument is not fair.

NOVARTIS VS GOVERNMENT OF INDIA

Importance of Section 3d of Indian Patent Act

Section 3 of Indian Patent Act defines what is not patentable. Section 3d gives out that the mere discovery of a new form of an old drug does not make it an invention. The section , as it is given in the Act is given below.

The Case of Novartis Vs Govt. of India

Novartis field patent applications for the cancer drug imatinib in most countries in 1993. The company was not able to do so in India, as the country was not granting product patents at that time. In 1997, Novartis applied for a more specific patent on the beta-crystalline polymorph of a mesylate salt of imatinib, i.e. imatinib mesylate, in order to try to obtain a patent monopoly in India.

    The case between Novartis India and the Indian Government being heard in Chennai High Court highlights the importance of the law with respect to patented drugs. The entire world is watching this case. I am giving the facts of the case as given by update of Lawyers collective HIV/AIDS Unit consisting of four lawyers.

  At Health Canada's request, Novartis Pharmaceuticals Canada Inc. is suspending the marketing and sales of Zelnorm (tegaserod hydrogen maleate) tablets in Canada to permit further evaluation of Zelnorm important safety information.  

At Health Canada's request, Novartis Pharmaceuticals Canada Inc. is suspending the marketing and sales of Zelnorm (tegaserod hydrogen maleate) tablets in Canada to permit further evaluation of Zelnorm important safety information.

     Reason for recall is, a recent retrospective analysis of pooled clinical trial data showed that the incidence of cardiovascular ischemic events such as myocardial infarction, stroke, and unstable angina pectoris in patients taking Zelnorm was higher than in those taking placebo.

  There were few products mentioned in Canadian Pharmaceutical Journal, CPJ, Jan-April 2007 editions, as they are going to be discontinued soon ......(some of them are discontinued already).

Biquin durules (quinidine bisulfate 250 mg extended release tablets by Astra Zeneca) have been discontinued. No other similar product exists on the market.

ZYTRAM XL : Purdue Pharma Inc. has introduced a new once daily ZYTRAM XL, a controlled release tramadol hydrochloride tablets, now available for Canadians with moderate pain.

ZYTRAM XL (tramadol hydrochloride controlled release tablets), an opioid analgesic, is indicated for the management of pain of moderate severity in adults who require treatment for several days.  ZYTRAM XL should not be used for minor pain that can be relieved by available (over the counter) analgesics.  ZYTRAM XL is for oral use only, must be swallowed whole and not to be chewed or crushed, since this can lead to the rapid release of tramadol and absorption of a potentially fatal dose of tramadol.  ZYTRAM XL is available in four different strengths such as, 150 mg. 200mg, 300mg and 400 mg once daily tablets.